Mirabegron Stada

Mirabegron, the active ingredient in Mirabegron Stada, is a Beta-3 adrenergic receptor agonist presented as an oral formulation for systemic use. It is indicated for the management of overactive bladder symptoms such as urgency, frequency and urge incontinence in adult patients. GNH USA supplies Mirabegron Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirabegron is used to treat conditions related to overactive bladder and its associated symptoms. - Overactive bladder: increases bladder capacity and reduces urgency episodes. - Urinary urgency: lessens the frequency of sudden, compelling urges to void. - Urge urinary incontinence: decreases the number of involuntary leakage episodes.

Adverse reactions may occur with Mirabegron therapy.

Common Side Effects: - Hypertension: elevated blood pressure observed in some patients. - Nasopharyngitis: mild upper respiratory tract infection symptoms. - Urinary tract infection: bacterial infection of the urinary system. - Headache: mild to moderate head pain.

Serious or Rare Side Effects: - Angioedema: swelling of deep skin layers that can affect breathing. - Severe hypertension: markedly high blood pressure requiring medical attention. - Urinary retention: difficulty emptying the bladder. - Bladder rupture: rare but serious injury to bladder wall.

Before initiating Mirabegron, several safety considerations should be observed. - Blood pressure assessment: measure baseline and monitor regularly. - Cardiovascular monitoring: watch for signs of tachycardia or arrhythmia. - Renal function evaluation: adjust use in patients with impaired kidney function. - Concomitant medication review: avoid combining with strong CYP2D6 or CYP3A4 inhibitors. - Uncontrolled hypertension avoidance: do not start in patients with markedly elevated blood pressure. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Mirabegron may interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase Mirabegron exposure. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): can raise plasma concentrations. - Monoamine oxidase inhibitors: risk of hypertensive crisis. - Anticholinergic agents: may exacerbate urinary retention.

Moderate Interactions (Monitor Closely): - Diuretics: potential additive effect on blood pressure. - Antihypertensive drugs: may require dose adjustment. - NSAIDs: increased risk of renal impairment.